Investopedia: Is "Less Bad" As Good As It Gets For Dendreon?

Investors who continue to stick by Dendreon (Nasdaq:DNDN), and its struggling prostate cancer therapy, Provenge, finally got a glimmer of good news after third quarter results. While Wall Street seemed to be pleased that this quarterly result was closer to "on target" (after a string of bad quarterly reports), Dendreon still has a lot of work ahead of it to turn this story around. I know Dendreon still has a loyal core of supporters, but it's difficult to argue for buying this stock when so many other drug companies offer better prospects for long-term gains.

Please continue reading here:
http://www.investopedia.com/stock-analysis/2012/Is-Less-Bad-As-Good-As-It-Gets-For-Dendreon-DNDN-JNJ-MDVN-SNY1105.aspx